S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
66,000% upside on tiny biotech? (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
66,000% upside on tiny biotech? (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
66,000% upside on tiny biotech? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
66,000% upside on tiny biotech? (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
66,000% upside on tiny biotech? (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
66,000% upside on tiny biotech? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
66,000% upside on tiny biotech? (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
66,000% upside on tiny biotech? (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
66,000% upside on tiny biotech? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
66,000% upside on tiny biotech? (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
66,000% upside on tiny biotech? (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
66,000% upside on tiny biotech? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
NASDAQ:AVXL

Anavex Life Sciences - AVXL Stock Forecast, Price & News

$10.93
-0.82 (-6.98%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$10.92
$11.90
50-Day Range
$7.65
$12.05
52-Week Range
$7.13
$15.24
Volume
1.42 million shs
Average Volume
1.33 million shs
Market Capitalization
$852.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.25

Anavex Life Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
314.0% Upside
$45.25 Price Target
Short Interest
Bearish
23.54% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
0.90mentions of Anavex Life Sciences in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.81) to ($0.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

464th out of 1,026 stocks

Biological Products, Except Diagnostic Industry

77th out of 167 stocks

AVXL stock logo

About Anavex Life Sciences (NASDAQ:AVXL) Stock

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Receive AVXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

AVXL Stock News Headlines

3 Secrets To Consistent Trading Success
Don't get caught in the trap of standing on the sidelines of intermarket correlation. The truth is that it’s impossible for you (or any human) to visualize and calculate complicated intermarket causations. Learn with A.I. which global markets have the most influence on a target market. Save a Seat for This Free Live Training. pixel
Anavex Life Sciences (AVXL) to Release Earnings on Tuesday
3 Secrets To Consistent Trading Success
Don't get caught in the trap of standing on the sidelines of intermarket correlation. The truth is that it’s impossible for you (or any human) to visualize and calculate complicated intermarket causations. Learn with A.I. which global markets have the most influence on a target market. Save a Seat for This Free Live Training. pixel
Anavex Life Sciences: The Little Company That Did
Anavex's (AVXL) Lead Alzheimer's Drug Meets Study Goal
Berenberg Bank Reaffirms Their Buy Rating on Anavex Life Sciences (AVXL)
Why Anavex Life Sciences Stock Is Surging Today
Anavex Life Sciences Shares Down 17% On Wider 4Q Loss
See More Headlines
Receive AVXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

AVXL Company Calendar

Last Earnings
11/28/2022
Today
2/08/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVXL
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$45.25
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+314.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-47,980,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.83 per share

Miscellaneous

Free Float
69,448,000
Market Cap
$852.87 million
Optionable
Optionable
Beta
0.77

Key Executives

  • Christopher U. Missling
    Chairman, President, CEO & Secretary
  • Stephan Toutain
    Chief Operating Officer
  • Sandra Boenisch
    Chief Financial Officer & Treasurer
  • Walter E. Kaufmann
    Chief Scientific Officer
  • Edward R. Hammond
    Chief Medical Officer













AVXL Stock - Frequently Asked Questions

Should I buy or sell Anavex Life Sciences stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVXL shares.
View AVXL analyst ratings
or view top-rated stocks.

What is Anavex Life Sciences' stock price forecast for 2023?

3 brokerages have issued 1-year price targets for Anavex Life Sciences' stock. Their AVXL share price forecasts range from $11.00 to $80.00. On average, they anticipate the company's stock price to reach $45.25 in the next year. This suggests a possible upside of 314.0% from the stock's current price.
View analysts price targets for AVXL
or view top-rated stocks among Wall Street analysts.

How have AVXL shares performed in 2023?

Anavex Life Sciences' stock was trading at $9.26 on January 1st, 2023. Since then, AVXL shares have increased by 18.0% and is now trading at $10.93.
View the best growth stocks for 2023 here
.

When is Anavex Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our AVXL earnings forecast
.

How were Anavex Life Sciences' earnings last quarter?

Anavex Life Sciences Corp. (NASDAQ:AVXL) issued its earnings results on Monday, November, 28th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.02.

What other stocks do shareholders of Anavex Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), LadRx (CYTR), Sanchez Energy (SN), Novavax (NVAX), Geron (GERN), VASCO Data Security International (VDSI), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

What is Anavex Life Sciences' stock symbol?

Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL."

Who are Anavex Life Sciences' major shareholders?

Anavex Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include UBS Group AG (0.40%), Swiss National Bank (0.24%), Private Advisor Group LLC (0.15%), Commonwealth Equity Services LLC (0.12%), Hennion & Walsh Asset Management Inc. (0.09%) and New York State Common Retirement Fund (0.06%). Insiders that own company stock include Athanasios Skarpelos, Elliot Favus, Elliot Favus, Peter DO Donhauser and Sandra Boenisch.
View institutional ownership trends
.

How do I buy shares of Anavex Life Sciences?

Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anavex Life Sciences' stock price today?

One share of AVXL stock can currently be purchased for approximately $10.93.

How much money does Anavex Life Sciences make?

Anavex Life Sciences (NASDAQ:AVXL) has a market capitalization of $852.87 million. The biotechnology company earns $-47,980,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis.

How can I contact Anavex Life Sciences?

Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The official website for the company is www.anavex.com. The biotechnology company can be reached via phone at (844) 689-3939 or via email at ir@anavex.com.

This page (NASDAQ:AVXL) was last updated on 2/9/2023 by MarketBeat.com Staff